35 -11 (85) 2025 - Salimjonov J.J., Khalimova Kh.M. - IL-6 AND SDC-1 LEVELS IN NEUROLOGICAL COMPLICATIONS FOLLOWING COVID-19 VACCINATION

IL-6 AND SDC-1 LEVELS IN NEUROLOGICAL COMPLICATIONS FOLLOWING COVID-19 VACCINATION

Salimjonov J.J. - Tashkent State Medical University

Khalimova Kh.M. - Tashkent State Medical University

Rashidova N.S.- Tashkent State Medical University

Resume

The article explores the role of interleukin-6 (IL-6) and syndecan-1 (SDC-1) in the pathogenesis of neurological complications following COVID-19 vaccination. Particular attention is paid to the interaction between inflammatory and endothelial mechanisms and their impact on the integrity of the blood–brain barrier. The findings suggest that increased cytokine activity and degradation of the endothelial glycocalyx may represent key links in the development of post-vaccination neurological phenotypes. The study supports the potential of IL-6 and SDC-1 as integrated biomarkers for early diagnosis, risk stratification, and monitoring of neurological complications after COVID-19 vaccination.

Keywords: COVID-19, vaccination, IL-6, SDC-1, endothelial dysfunction, neurological complications.

First page

198

Last page

202

For citation:Salimjonov J.J., Khalimova Kh.M., Rashidova N.S. - IL-6 AND SDC-1 LEVELS IN NEUROLOGICAL COMPLICATIONS FOLLOWING COVID-19 VACCINATION//New Day in Medicine 11(85)2025 198-202 https://newdayworldmedicine.com/en/new_day_medicine/11-85-2025

List of References

1. World Health Organization. COVID-19 Vaccination Dashboard. WHO, 2023.
2. Chen Y., et al. Neurological complications after COVID-19 vaccination: a systematic review. // J Neurol Sci. 2023;448:120646.
3. Patone M., et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. // Nat Med. 2021;27:2144–2153.
4. Finsterer J. Excessive immune response and neural injury after COVID-19 vaccination. // Clin Neuroimmunol. 2022;3(1):45–53.
5. Garg R.K., et al. Post-COVID-19 vaccination neurological complications: An updated review. // Front Neurol. 2024;15:1291.
6. Choy E.H., et al. Interleukin-6 pathway in inflammation and disease. // Nat Rev Rheumatol. 2020;16(6):337–348.
7. Gupta A., et al. IL-6 and the Blood–Brain Barrier: neuroinflammatory link in CNS disorders. // Front Immunol. 2022;13:847992.
8. Paul R., et al. IL-6-mediated signaling in neuroinflammation and neurodegeneration. // Neurochem Int. 2024;178:105030.
9. Song E., et al. IL-6 trans-signaling and the brain microvascular endothelium. // J Neuroinflammation. 2023;20(1):211.
10. Reitsma S., et al. The endothelial glycocalyx: composition, functions, and visualization. // Pflugers Arch. 2007;454:345–359.
11. Alphonsus C.S., Rodseth R.N. The endothelial glycocalyx: a review of current research and clinical implications. // Anaesthesia. 2014;69:777–789.
12. Becker B.F., et al. Degradation of the endothelial glycocalyx in sepsis and inflammatory diseases. // Cardiovasc Res. 2015;107(3):233–243.
13. Fraser D.D., et al. Endothelial glycocalyx damage in COVID-19 patients correlates with SDC-1 levels. // Crit Care. 2021;25(1):331.
14. Ikeda M., et al. Circulating syndecan-1 predicts disease severity in patients with COVID-19. J Infect Chemother. 2022;28:546–552.
15. Hayashi K., et al. SDC-1 as a biomarker of endothelial injury in severe COVID-19. // Sci Rep. 2023;13:20487.
16. Mehta P., et al. The interplay between cytokines and endothelial glycocalyx in systemic inflammation. // Trends Mol Med. 2023;29(5):390–404.
17. Zhao F., et al. Syndecan-1 and blood–brain barrier disruption in ischemic stroke. // Front Neurol. 2022;13:854920.
18. Hosseini R., et al. A review of neurological side effects of COVID-19 vaccination. // Eur J Med Res. 2023;28(1):34.
19. Халимова Х.М., Рашидова Н.С., Салимжонов Ж.Ж. Неврологические осложнения после вакцинации COVID-19. // Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(12):13–19.

    file

    download